Benzalkonium Chloride: An Irritant and Sensitizer
| Autor: | Jahdonna Isaac, Pamela L. Scheinman |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Erythema Dermatology Cross Reactions 030207 dermatology & venereal diseases 03 medical and health sciences Benzalkonium chloride 0302 clinical medicine Edema medicine Humans Immunology and Allergy In patient Allergic contact dermatitis Sensitization Aged Retrospective Studies business.industry Middle Aged Patch Tests medicine.disease Ammonium compounds 030104 developmental biology medicine.anatomical_structure Dermatitis Allergic Contact Dermatitis Irritant Female biological phenomena cell phenomena and immunity medicine.symptom Benzalkonium Compounds business Contact dermatitis medicine.drug |
| Zdroj: | Dermatitis. 28:346-352 |
| ISSN: | 2162-5220 1710-3568 |
| DOI: | 10.1097/der.0000000000000316 |
| Popis: | Background Benzalkonium chloride (BAK) is a known irritant, and potentially cross-reacting quaternary ammonium compounds are commonly used as preservatives in personal care products. Objective The aim of the study was to review positive reactions to BAK in 615 patients patch tested for suspected allergic contact dermatitis. Methods A retrospective chart review was performed in 615 patients patch tested from June 2015 to October 2016. All patients were tested to a Modified American Contact Dermatitis Society core series of 70 allergens including BAK (0.1% aqueous). Initial readings were performed at 48 hours with final readings performed between 72 and 168 hours. Results were graded as + (weak: papules and erythema), ++ (strong: papules and edema or vesicles), or +++ (extreme: coalescing vesicles, spreading or bullous reactions). Results A total of 141 men (23%) and 475 women (77%) were tested (mean age, 49 years). Four hundred thirty-two (70%) were atopic. Of 615 patients, 198 (32%) tested positive to BAK, and 64 (10%) had ++ or +++ reactions at their final reading. On average, BAK-positive patients were using at least 1 product containing BAK or possible cross-reactors. Conclusions Widespread exposure to irritants in dermatitis patients can predispose to sensitization. Products containing BAK or potential cross-reactors should be used carefully in patients with compromised skin barriers. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|